Literature DB >> 1463423

Response of the retinal pigment epithelium to selective photocoagulation.

J Roider1, N A Michaud, T J Flotte, R Birngruber.   

Abstract

Multiple short argon laser pulses can coagulate the retinal pigment epithelium selectively, while sparing the adjacent neural retina and choroid; in contrast, continuous-wave laser irradiation typically damages the neural retina and choroid. The healing response to selective photocoagulation of the retinal pigment epithelium was studied in rabbits during a period of 4 weeks. The lesions were never visible ophthalmoscopically. During the healing period, the epithelium was reformed by a single sheet of hypertrophic retinal pigment epithelial cells. In contrast to continuous-wave photocoagulation, only minimal inflammatory response was found. Retinal pigment epithelial cells showed clear signs of viability, eg, phagocytized outer segments. The local edema in the photoreceptor layer and subretinal space found in the early stage disappeared when the blood-retinal barrier was reestablished. The choriocapillaris remained unaffected. No subsequent damage to the photoreceptors was found. This type of photocoagulation may be useful for retinal pigment epithelium-related diseases, eg, diffuse diabetic macular edema.

Entities:  

Mesh:

Year:  1992        PMID: 1463423     DOI: 10.1001/archopht.1992.01080240126045

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  53 in total

Review 1.  Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.

Authors:  G Soubrane; N M Bressler
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Selective cell targeting with light-absorbing microparticles and nanoparticles.

Authors:  Costas M Pitsillides; Edwin K Joe; Xunbin Wei; R Rox Anderson; Charles P Lin
Journal:  Biophys J       Date:  2003-06       Impact factor: 4.033

3.  Conditioned medium from mixed retinal pigmented epithelium and Müller cell cultures reduces in vitro permeability of retinal vascular endothelial cells.

Authors:  M Tretiach; M C Madigan; M C Gillies
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

4.  Selective retina therapy in patients with central serous chorioretinopathy.

Authors:  H Elsner; E Pörksen; C Klatt; A Bunse; D Theisen-Kunde; R Brinkmann; R Birngruber; H Laqua; J Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

5.  [Selective RPE laser treatment with a scanned cw laser beam in rabbits].

Authors:  C Framme; C Alt; S Schnell; R Brinkmann; C P Lin
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

6.  "Light" versus "classic" laser treatment for clinically significant diabetic macular oedema.

Authors:  F Bandello; A Polito; M Del Borrello; N Zemella; M Isola
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

7.  Grid laser photocoagulation for macular oedema in uveitis or the Irvine-Gass syndrome.

Authors:  C W Lardenoye; M J van Schooneveld; W Frits Treffers; A Rothova
Journal:  Br J Ophthalmol       Date:  1998-09       Impact factor: 4.638

8.  Selective retina therapy (SRT) in patients with geographic atrophy due to age-related macular degeneration.

Authors:  Philipp Prahs; Andreas Walter; Roman Regler; Dirk Theisen-Kunde; Reginald Birngruber; Ralf Brinkmann; Carsten Framme
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-22       Impact factor: 3.117

Review 9.  Statement and supplementary statement from the BVA, the DOG, and the RG on laser treatment of drusen in age-related macular degeneration (AMD) : August 2017, update October 2018.

Authors: 
Journal:  Ophthalmologe       Date:  2020-01       Impact factor: 1.059

10.  Autofluorescence imaging after selective RPE laser treatment in macular diseases and clinical outcome: a pilot study.

Authors:  C Framme; R Brinkmann; R Birngruber; J Roider
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.